{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:20:44Z","timestamp":1773451244036,"version":"3.50.1"},"reference-count":64,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"unspecified","delay-in-days":142,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0266462325000091_sec1\">\n\t    <jats:title>Objectives<\/jats:title>\n\t    <jats:p>This study aimed to evaluate the required test characteristics that a psoriatic arthritis (PsA) biomarker test would need to achieve to be considered cost-effective.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0266462325000091_sec2\" sec-type=\"methods\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>We adapted an existing Markov model to compare a hypothetical biomarker with current practice. The model followed a patient cohort aged 45\u00a0years with moderate psoriasis (PsO) in which PsA was prevalent but unrecognized over a 40-year time horizon. Patients were assumed to be routinely seen at a dermatology clinic. In the current practice arm, patients with PsA were clinically detected. In the biomarker arm, a hypothetical test was assumed to be administered at baseline. Patients who screened positive would accept a combination of conventional disease-modifying antirheumatic drugs and targeted treatment to slow disease progression. Progression was modeled as linear changes in Health Assessment Questionnaire (HAQ) scores. We varied the sensitivity, specificity, and biomarker price based on current development progress. Scenario analyses considered alternative patient cohorts with mild and severe PsO separately.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0266462325000091_sec3\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>The base case showed that a biomarker test with 70 percent sensitivity, 80 percent specificity, and a price of US$500 would be cost-effective (incremental cost-effectiveness ratio US$47,566 per quality-adjusted life-year [QALY]). Three-way analyses showed that a test with 80 percent specificity could be cost-effective at a US$50,000 per QALY threshold with a sensitivity as low as 66 percent at US$500. Only a near-perfect test would be cost-effective at a US$1,000 price point. Results were sensitive to HAQ progression under treatment, therapy costs, and the patient population.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0266462325000091_sec4\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusion<\/jats:title>\n\t    <jats:p>This study supports the continued product development of candidate PsA biomarkers.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s0266462325000091","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T07:45:59Z","timestamp":1747986359000},"source":"Crossref","is-referenced-by-count":3,"title":["Identifying characteristics for a cost-effective psoriatic arthritis biomarker test: a development-focused health technology assessment"],"prefix":"10.1017","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3359-5552","authenticated-orcid":false,"given":"Alexander C.T.","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vathany","family":"Kulasingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eldon","family":"Spackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Bansback","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"S0266462325000091_r26","first-page":"260","article-title":"Modeling in early stages of technology development: Is an iterative approach needed?","volume":"9","author":"Drummond","year":"2019","journal-title":"Int J Health Policy Manag"},{"key":"S0266462325000091_r1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"S0266462325000091_r39","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160941"},{"key":"S0266462325000091_r18","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24110"},{"key":"S0266462325000091_r59","first-page":"e49443","article-title":"Challenges in diagnosing psoriatic arthritis in primary care: A meta-ethnographic study","volume":"15","author":"Ohta","year":"2023","journal-title":"Cureus"},{"key":"S0266462325000091_r28","unstructured":"28. NPF. NPF-funded research: Multi-omic diagnostic test for psoriatic arthritis in psoriasis patients. Available from: https:\/\/www.psoriasis.org\/multi-omic-diagnostic-test-for-psoriatic-arthritis-in-psoriasis-patients\/."},{"key":"S0266462325000091_r16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004062"},{"key":"S0266462325000091_r38","doi-asserted-by":"publisher","DOI":"10.3310\/hta21560"},{"key":"S0266462325000091_r41","unstructured":"41. Physician Fee Schedule | CMS. Available from: https:\/\/www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched."},{"key":"S0266462325000091_r44","unstructured":"44. Centers for Medicare & Medicaid Services. National Average Drug Acquisition Cost. Available from: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/pharmacy-pricing\/index.html."},{"key":"S0266462325000091_r25","doi-asserted-by":"publisher","DOI":"10.2165\/11593380-000000000-00000"},{"key":"S0266462325000091_r57","unstructured":"57. How BLS measures price change for medical care services in the consumer price index: U.S. Bureau of Labor Statistics. Available from: https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm."},{"key":"S0266462325000091_r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"S0266462325000091_r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.001"},{"key":"S0266462325000091_r46","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-00765-2"},{"key":"S0266462325000091_r62","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000374"},{"key":"S0266462325000091_r15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214746"},{"key":"S0266462325000091_r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.010"},{"key":"S0266462325000091_r35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker245"},{"key":"S0266462325000091_r51","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"S0266462325000091_r7","doi-asserted-by":"publisher","DOI":"10.3390\/proteomes6010005"},{"key":"S0266462325000091_r61","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1020-3"},{"key":"S0266462325000091_r40","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X11401031"},{"key":"S0266462325000091_r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.044"},{"key":"S0266462325000091_r22","first-page":"16639","article-title":"Recent advances in the management of psoriatic arthritis: Practical considerations","volume":"134","author":"Harrison","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"S0266462325000091_r20","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1752667"},{"key":"S0266462325000091_r54","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"S0266462325000091_r6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.723944"},{"key":"S0266462325000091_r10","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-013-0032-x"},{"key":"S0266462325000091_r5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05713-8"},{"key":"S0266462325000091_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"S0266462325000091_r50","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00887-6"},{"key":"S0266462325000091_r63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054539"},{"key":"S0266462325000091_r30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"S0266462325000091_r27","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232100026X"},{"key":"S0266462325000091_r31","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0167"},{"key":"S0266462325000091_r48","first-page":"997","article-title":"Health care utilization and costs associated with functional status in patients with psoriatic arthritis","volume":"28","author":"Ogdie","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"S0266462325000091_r12","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1942423"},{"key":"S0266462325000091_r49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg384"},{"key":"S0266462325000091_r55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001170"},{"key":"S0266462325000091_r17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"S0266462325000091_r24","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0033"},{"key":"S0266462325000091_r60","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170148"},{"key":"S0266462325000091_r2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19144.1"},{"key":"S0266462325000091_r14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152223"},{"key":"S0266462325000091_r8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0"},{"key":"S0266462325000091_r11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05839-9"},{"key":"S0266462325000091_r9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03463.x"},{"key":"S0266462325000091_r56","first-page":"63","article-title":"United States life tables, 2020","volume":"71","author":"Arias","year":"2022","journal-title":"Nat Vital Stat Rep"},{"key":"S0266462325000091_r3","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"S0266462325000091_r23","unstructured":"23. ASPE. Cost drivers in the development and validation of biomarkers used in drug development. ASPE. Available from: https:\/\/aspe.hhs.gov\/reports\/cost-drivers-development-validation-biomarkers-used-drug-development."},{"key":"S0266462325000091_r36","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"S0266462325000091_r13","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00034-6"},{"key":"S0266462325000091_r58","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05391-y"},{"key":"S0266462325000091_r45","unstructured":"45. Office of Procurement, Acquisition and Logistics. Veterans Affairs Federal Supply Schedule. Available from: https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp."},{"key":"S0266462325000091_r42","unstructured":"42. Clinical Laboratory Fee Schedule Files | CMS. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files."},{"key":"S0266462325000091_r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.27784"},{"key":"S0266462325000091_r4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae198"},{"key":"S0266462325000091_r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"S0266462325000091_r21","first-page":"13","article-title":"Basic Science Session 1. Biomarkers for psoriatic arthritis treatment response and joint damage progression: An update on 2 industry-GRAPPA projects","volume":"49","author":"Waddington","year":"2022","journal-title":"J Rheumatol"},{"key":"S0266462325000091_r37","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1593-8"},{"key":"S0266462325000091_r34","volume-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: A systematic review and economic evaluation","author":"Rodgers","year":"2011"},{"key":"S0266462325000091_r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.06.013"},{"key":"S0266462325000091_r64","unstructured":"64. Target Product Profile database. Available from: https:\/\/www.who.int\/tools\/target-product-profile-database."}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462325000091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:24:02Z","timestamp":1748424242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462325000091\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S0266462325000091"],"URL":"https:\/\/doi.org\/10.1017\/s0266462325000091","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e29"}}